Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile
Onco-Innovations has announced that its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound has demonstrated enhanced PNKP inhibitor delivery with minimal toxicity. A June 2021 study by the University of Alberta revealed that the technology was well-tolerated at therapeutic doses in mice with colorectal cancer, showing no signs of toxicity such as weight loss or adverse effects. This formulation, tested as a targeted therapy for PTEN-deficient colorectal cancer, showed promising results in both in vitro and in vivo evaluations.
The study involved treating mice with the PKNP nanoparticle formulation (NP/A83) over a 22-day period, while a control group received placebo injections. Both biochemical and histopathological examinations confirmed the absence of toxicity in major organs. Dose-escalating toxicity studies on healthy CD-1 mice indicated that both free and nano-encapsulated PNKP inhibitors were safe at doses of ≤50 mg/kg. The findings suggest potential for developing safer and more effective cancer treatments with fewer side effects.
Thomas O'Shaughnessy, CEO, emphasized the technology's promise for future therapeutic development due to its low toxicity profile, laying a foundation for continued research and development.
Onco-Innovations ha annunciato che la sua formulazione di nanoparticelle di seconda generazione del composto Polynucleotide Kinase 3'-Phosphatase (PNKP) ha dimostrato un miglioramento nella somministrazione degli inibitori PNKP con una tossicità minima. Uno studio del giugno 2021 condotto dall'Università dell'Alberta ha rivelato che la tecnologia era ben tollerata a dosi terapeutiche in topi affetti da cancro colorettale, senza segni di tossicità come perdita di peso o effetti avversi. Questa formulazione, testata come terapia mirata per il cancro colorettale carente di PTEN, ha mostrato risultati promettenti sia nelle valutazioni in vitro che in vivo.
Lo studio ha coinvolto il trattamento di topi con la formulazione di nanoparticelle PKNP (NP/A83) per un periodo di 22 giorni, mentre un gruppo di controllo ha ricevuto iniezioni di placebo. Esami biochimici e istopatologici hanno confermato l'assenza di tossicità negli organi principali. Studi di tossicità con dosi crescenti su topi CD-1 sani hanno indicato che sia gli inibitori PNKP liberi che quelli nano-incapsulati erano sicuri a dosi di ≤50 mg/kg. I risultati suggeriscono un potenziale per lo sviluppo di trattamenti oncologici più sicuri ed efficaci con meno effetti collaterali.
Thomas O'Shaughnessy, CEO, ha sottolineato la promessa della tecnologia per lo sviluppo terapeutico futuro grazie al suo profilo di bassa tossicità, ponendo le basi per una continua ricerca e sviluppo.
Onco-Innovations ha anunciado que su formulación de nanopartículas de segunda generación del compuesto Polynucleotide Kinase 3'-Phosphatase (PNKP) ha demostrado una entrega mejorada de inhibidores de PNKP con una toxicidad mínima. Un estudio de junio de 2021 realizado por la Universidad de Alberta reveló que la tecnología fue bien tolerada a dosis terapéuticas en ratones con cáncer colorrectal, sin signos de toxicidad como pérdida de peso o efectos adversos. Esta formulación, probada como terapia dirigida para el cáncer colorrectal deficiente en PTEN, mostró resultados prometedores tanto en evaluaciones in vitro como in vivo.
El estudio involucró el tratamiento de ratones con la formulación de nanopartículas PKNP (NP/A83) durante un período de 22 días, mientras que un grupo de control recibió inyecciones de placebo. Exámenes bioquímicos e histopatológicos confirmaron la ausencia de toxicidad en los órganos principales. Estudios de toxicidad con dosis crecientes en ratones CD-1 sanos indicaron que tanto los inhibidores de PNKP libres como los nanoencapsulados eran seguros a dosis de ≤50 mg/kg. Los hallazgos sugieren un potencial para desarrollar tratamientos contra el cáncer más seguros y efectivos con menos efectos secundarios.
Thomas O'Shaughnessy, CEO, enfatizó la promesa de la tecnología para el desarrollo terapéutico futuro debido a su bajo perfil de toxicidad, sentando las bases para una investigación y desarrollo continuos.
Onco-Innovations는 Polynucleotide Kinase 3'-Phosphatase (PNKP) 화합물의 2세대 나노입자 제형이 최소한의 독성으로 PNKP 억제제 전달을 향상시켰다고 발표했습니다. 2021년 6월 알버타 대학교의 연구에 따르면 이 기술은 대장암에 걸린 쥐에서 치료 용량으로 잘 견딜 수 있었으며, 체중 감소나 부작용과 같은 독성의 징후가 나타나지 않았습니다. PTEN 결핍 대장암에 대한 표적 치료로 테스트된 이 제형은 시험관 내 및 생체 내 평가에서 유망한 결과를 보여주었습니다.
이 연구는 쥐를 22일 동안 PKNP 나노입자 제형(NP/A83)으로 치료했으며, 대조군은 위약 주사를 받았습니다. 생화학적 및 조직병리학적 검사는 주요 장기에서 독성의 부재를 확인했습니다. 건강한 CD-1 쥐를 대상으로 한 용량 증가 독성 연구에서는 자유 및 나노 캡슐화된 PNKP 억제제가 ≤50 mg/kg의 용량에서 안전하다는 것을 나타냈습니다. 이 발견은 부작용이 적은 더 안전하고 효과적인 암 치료법 개발의 가능성을 제시합니다.
CEO인 Thomas O'Shaughnessy는 낮은 독성 프로필 덕분에 향후 치료 개발에 대한 기술의 약속을 강조하며 지속적인 연구 및 개발의 기초를 마련했습니다.
Onco-Innovations a annoncé que sa formulation de nanoparticules de deuxième génération du composé Polynucleotide Kinase 3'-Phosphatase (PNKP) a démontré une meilleure délivrance des inhibiteurs PNKP avec une toxicité minimale. Une étude de juin 2021 menée par l'Université de l'Alberta a révélé que la technologie était bien tolérée à des doses thérapeutiques chez des souris atteintes de cancer colorectal, sans signes de toxicité tels que perte de poids ou effets indésirables. Cette formulation, testée comme thérapie ciblée pour le cancer colorectal déficient en PTEN, a montré des résultats prometteurs tant dans les évaluations in vitro qu'in vivo.
L'étude a impliqué le traitement de souris avec la formulation de nanoparticules PKNP (NP/A83) sur une période de 22 jours, tandis qu'un groupe témoin a reçu des injections de placebo. Des examens biochimiques et histopathologiques ont confirmé l'absence de toxicité dans les organes principaux. Des études de toxicité à doses croissantes sur des souris CD-1 saines ont indiqué que les inhibiteurs PNKP, qu'ils soient libres ou nano-encapsulés, étaient sûrs à des doses de ≤50 mg/kg. Les résultats suggèrent un potentiel pour le développement de traitements anticancéreux plus sûrs et plus efficaces avec moins d'effets secondaires.
Thomas O'Shaughnessy, PDG, a souligné la promesse de la technologie pour le développement thérapeutique futur en raison de son profil de faible toxicité, posant ainsi les bases d'une recherche et d'un développement continus.
Onco-Innovations hat angekündigt, dass ihre Nanopartikel-Formulierung der zweiten Generation des Polynucleotide Kinase 3'-Phosphatase (PNKP) Verbindungen eine verbesserte Abgabe von PNKP-Inhibitoren mit minimaler Toxizität gezeigt hat. Eine Studie aus dem Juni 2021 der Universität Alberta ergab, dass die Technologie bei therapeutischen Dosen bei Mäusen mit kolorektalem Krebs gut vertragen wurde, ohne Anzeichen von Toxizität wie Gewichtsverlust oder Nebenwirkungen. Diese Formulierung, die als gezielte Therapie für PTEN-defizienten kolorektalen Krebs getestet wurde, zeigte vielversprechende Ergebnisse sowohl in vitro als auch in vivo.
In der Studie wurden Mäuse über einen Zeitraum von 22 Tagen mit der PKNP-Nanopartikel-Formulierung (NP/A83) behandelt, während eine Kontrollgruppe Placebo-Injektionen erhielt. Biochemische und histopathologische Untersuchungen bestätigten das Fehlen von Toxizität in den Hauptorganen. Dosissteigernde Toxizitätsstudien an gesunden CD-1-Mäusen zeigten, dass sowohl freie als auch nano-verkapselte PNKP-Inhibitoren bei Dosen von ≤50 mg/kg sicher waren. Die Ergebnisse deuten auf das Potenzial hin, sicherere und effektivere Krebsbehandlungen mit weniger Nebenwirkungen zu entwickeln.
Thomas O'Shaughnessy, CEO, betonte das Versprechen der Technologie für die zukünftige therapeutische Entwicklung aufgrund ihres niedrigen Toxizitätsprofils und legte damit den Grundstein für eine fortlaufende Forschung und Entwicklung.
- The second-generation nanoparticle formulation demonstrated enhanced PNKP inhibitor delivery with minimal toxicity.
- The technology was well-tolerated at therapeutic doses in mice with colorectal cancer, showing no signs of toxicity.
- Biochemical and histopathological examinations confirmed the absence of toxicity in major organs.
- Dose-escalating toxicity studies indicated safety at doses of ≤50 mg/kg.
- None.
VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound (the "Technology"), specifically that it has demonstrated enhanced PNKP inhibitor delivery, enabling solubilization with minimal toxicity, in a June 2021 study[1] conducted by researchers at the University of Alberta, Canada. The study demonstrated that the Technology was well-tolerated, even at therapeutic doses to mice with colorectal cancer, making it a promising candidate for further research and development. This finding is highly relevant, as low toxicity indicates the potential for fewer side effects, potentially allowing for use to enhance more effective and safer treatment options.
In in-vivo studies, mice with colorectal cancer tumors were treated over a 22-day period with Onco's PKNP nanoparticle formulation (NP/A83), while a control group received placebo injections. The study involved both in vitro and in vivo evaluations of a nano-encapsulated potent lead PNKP inhibitor, which was tested as a new targeted therapy for PTEN-deficient colorectal cancer (CRC). Throughout the study, the treatment was well tolerated, with no evidence of toxicity, such as weight loss or adverse effects, observed in the test subjects. Biochemical and histopathological examination of major organs confirmed the absence of toxicity in mice treated with the nanoparticle formulation. The dose-escalating toxicity studies on healthy CD-1 mice revealed that both free and nano-encapsulated PNKP inhibitors were safe at doses of ≤50 mg/kg, based on weight changes and blood analysis.[2]
Ensuring a low toxicity profile is essential for developing safer and more effective cancer treatments. By demonstrating minimal toxicity in preclinical models, Onco's Technology shows promise for pursuing therapies with fewer side effects. Under Health Canada regulations, drugs must undergo rigorous testing in animal models (in vivo) or in cell cultures (in vitro) to assess toxicity at doses intended to produce therapeutic effects.
"The study has shown that our PKNP technology has promise for future therapeutic development, particularly due to its low toxicity profile. The ability of this technology to deliver enhanced PNKP inhibition with minimal side effects lays a solid foundation for our continued research and development plans. We are excited about the future of this compound and its potential to provide safer and more effective therapies," said Thomas O'Shaughnessy, CEO of the Company.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented groundbreaking technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Technology, the Company's ability to complete future research and development activities with respect thereto, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Technology, the failure to complete further research and development activities in respect thereto, the failure to receive regulatory approval in respect of the Technology, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
[1]A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer" in Journal of Controlled Release, Volume 334, June 2021: pp. 335-352
[2]A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer" in Journal of Controlled Release, Volume 334, June 2021: pp. 335-352
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What does the ONNVF buyback mean for shareholders?
What is the significance of Onco-Innovations' PKNP technology?
How was the PKNP technology tested in the study?
What were the results of the PKNP technology study on mice?
What is the potential impact of the PKNP technology on cancer treatment?
What did the dose-escalating toxicity studies reveal about the PKNP technology?
What did the CEO of Onco-Innovations say about the PKNP technology?
